ALBI and PALBI Scores and HCC Prognosis

Completed

• Conditions: Hepatocellular Carcinoma (HCC) Prognosis

• Registration Number: NCT05720195
• Lead Sponsor: Sohag University

Brief Summary

To compare the predictive ability of ALBI and PALBI grades with CTP and MELD scores.

To investigate the efficacy of ALBI and PALBI grades for predicting the prognosis of HCC and overall survival among different modalities of treatment.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2019-01-01
• Primary Completion: 2022-12-31
• Study Completion: 2022-12-31
• Status Verified: 2023-01
• Study First Submitted: 2023-01-19
• Study First Submitted QC: 2023-01-30
• Last Update Submitted: 2023-01-30
• Study First Posted: 2023-02-09
• Last Update Posted: 2023-02-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 645

Inclusion Criteria

• The diagnosis of HCC will be based on the presence of an arterial hypervascular focal lesion > 2 cm with rapid wash-out with a single imaging modality (triphasic computed tomography (CT), or dynamic magnetic resonance imaging (MRI)) or two imaging modalities demonstrating the before mentioned feature for lesions < 2 cm with or without elevated serum alpha-fetoprotein (AFP) levels.

Read More

Exclusion Criteria

• Patients below 18 years old.
• Patients with pre-existing other malignancies.
• Patients with pre-existing gall bladder stones, benign strictures, or other biliary diseases.
• Patients with pre-existing haematologic disorders.
• Patients with proteinuria.
• Missed follow-up.

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Overall survival among HCC patients as assessed by the albumin-bilirubin (ALBI) score	2 years	We will compare the ability of ALBI score to predict overall survival among HCC patients versus Child Pugh and MELD scores
Overall survival among HCC patients as assessed by the platelet-albumin-bilirubin (PALBI) score	2 years	We will compare the ability of PALBI score to predict overall survival among HCC patients versus Child Pugh and MELD scores

Secondary Outcome Measures

Name	Time	Method
Overall survival among HCC patients according to treatment modality as assessed by the albumin-bilirubin (ALBI) score	2 years	We will compare the ability of ALBI score to predict overall survival among HCC patients stratified according to treatment modality (Surgical resection, local ablation, trans-arterial chemoembolization, sorafenib and best supportive care)
Overall survival among HCC patients according to treatment modality as assessed by the platelet-albumin-bilirubin (PALBI)	2 years	We will compare the ability of PALBI score to predict overall survival among HCC patients stratified according to treatment modality (Surgical resection, local ablation, trans-arterial chemoembolization, sorafenib and best supportive care)

Trial Locations

Locations (1)

Sohag University; 🇪🇬 Sohag, Egypt